NLRP3 and metabolic dysfunction-associated steatotic liver disease: Recently, findings related to NLRP3 inflammasome-associated agents and inhibitors for use in treating NAFLD/NASH in experimental models have supported this therapeutic approach and been demonstrated to have positive effects.